CIGLIOLA, ANTONIO
CIGLIOLA, ANTONIO
Facoltà di Medicina e Chirurgia
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC)
2024-01-01 Mercinelli, C.; Raggi, D.; Cigliola, A.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Moschini, M.; Re, C.; Avesani, G.; Briganti, A.; Montorsi, F.; Ross, J. S.; Graf, R.; Pavlick, D. C.; Necchi, A.
Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study
2024-01-01 Reike, M. J.; Raggi, D.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; De Padua, T. C.; Black, P. C.; Gibb, E. A.; Necchi, A.
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC)
2024-01-01 Mercinelli, C.; Basile, G.; Raggi, D.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; Padua, T. C. D.; Colecchia, M.; Colombo, R.; Moschini, M.; Re, C.; Avesani, G.; Brembilla, G.; De Cobelli, F.; Briganti, A.; Pavlick, D. C.; Ross, J. S.; Montorsi, F.; Necchi, A.
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer
2024-01-01 Mercinelli, C.; Moschini, M.; Cigliola, A.; Mattorre, B.; Tateo, V.; Basile, G.; Cogrossi, L. L.; Maiorano, B. A.; Patane, D. A.; Raggi, D.; Pastorino, G. L.; Re, C.; Colecchia, M.; Luciano, R.; Colombo, R.; Brembilla, G.; De Cobelli, F.; Briganti, A.; Pavlick, D. C.; Ross, J. S.; Montorsi, F.; Bellone, M.; Necchi, A.
Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report
2024-01-01 Villatore, A.; Bosi, C.; Pomaranzi, C.; Cigliola, A.; Tateo, V.; Mercinelli, C.; Vignale, D.; Rizzo, S.; Necchi, A.; Peretto, G.
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI
2024-01-01 Brembilla, G.; Basile, G.; Cosenza, M.; Giganti, F.; Del Prete, A.; Russo, T.; Pennella, R.; Lavalle, S.; Raggi, D.; Mercinelli, C.; Tateo, V.; Cigliola, A.; Patane, D.; Crupi, E.; Giannatempo, P.; Messina, A.; Calareso, G.; Martini, A.; Bandini, M.; Moschini, M.; Cardone, G.; Briganti, A.; Montorsi, F.; Necchi, A.; De Cobelli, F.
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel
2024-01-01 Tateo, V.; Cigliola, A.; Mercinelli, C.; Agarwal, N.; Grivas, P.; Kamat, A. M.; Gibb, E. A.; Moschini, M.; Brausi, M.; Dyrskjot, L.; Loriot, Y.; Gupta, S.; Colecchia, M.; Spiess, P. E.; Ross, J. S.; Necchi, A.
The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC)
2024-01-01 Tateo, V.; Gibb, E.; Mercinelli, C.; Raggi, D.; Cigliola, A.; Patane, D. A.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Avesani, G.; Briganti, A.; Montorsi, F.; Santini, D.; Necchi, A.
Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials
2024-01-01 Cigliola, A.; Basile, G.; Mercinelli, C.; Raggi, D.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Colombo, R.; Avesani, G.; Re, C.; Briganti, A.; Montorsi, F.; Necchi, A.
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer
2024-01-01 Necchi, A.; Basile, G.; Gibb, E. A.; Raggi, D.; Calareso, G.; De Padua, T. C.; Patane, D.; Crupi, E.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Giannatempo, P.; Moschini, M.; Briganti, A.; Montorsi, F.; Messina, A.; Ross, J. S.; Pavlick, D.; De Cobelli, F.; Brembilla, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC) | 1-gen-2024 | Mercinelli, C.; Raggi, D.; Cigliola, A.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Moschini, M.; Re, C.; Avesani, G.; Briganti, A.; Montorsi, F.; Ross, J. S.; Graf, R.; Pavlick, D. C.; Necchi, A. | |
| Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study | 1-gen-2024 | Reike, M. J.; Raggi, D.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; De Padua, T. C.; Black, P. C.; Gibb, E. A.; Necchi, A. | |
| First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) | 1-gen-2024 | Mercinelli, C.; Basile, G.; Raggi, D.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; Padua, T. C. D.; Colecchia, M.; Colombo, R.; Moschini, M.; Re, C.; Avesani, G.; Brembilla, G.; De Cobelli, F.; Briganti, A.; Pavlick, D. C.; Ross, J. S.; Montorsi, F.; Necchi, A. | |
| First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer | 1-gen-2024 | Mercinelli, C.; Moschini, M.; Cigliola, A.; Mattorre, B.; Tateo, V.; Basile, G.; Cogrossi, L. L.; Maiorano, B. A.; Patane, D. A.; Raggi, D.; Pastorino, G. L.; Re, C.; Colecchia, M.; Luciano, R.; Colombo, R.; Brembilla, G.; De Cobelli, F.; Briganti, A.; Pavlick, D. C.; Ross, J. S.; Montorsi, F.; Bellone, M.; Necchi, A. | |
| Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report | 1-gen-2024 | Villatore, A.; Bosi, C.; Pomaranzi, C.; Cigliola, A.; Tateo, V.; Mercinelli, C.; Vignale, D.; Rizzo, S.; Necchi, A.; Peretto, G. | |
| Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI | 1-gen-2024 | Brembilla, G.; Basile, G.; Cosenza, M.; Giganti, F.; Del Prete, A.; Russo, T.; Pennella, R.; Lavalle, S.; Raggi, D.; Mercinelli, C.; Tateo, V.; Cigliola, A.; Patane, D.; Crupi, E.; Giannatempo, P.; Messina, A.; Calareso, G.; Martini, A.; Bandini, M.; Moschini, M.; Cardone, G.; Briganti, A.; Montorsi, F.; Necchi, A.; De Cobelli, F. | |
| Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel | 1-gen-2024 | Tateo, V.; Cigliola, A.; Mercinelli, C.; Agarwal, N.; Grivas, P.; Kamat, A. M.; Gibb, E. A.; Moschini, M.; Brausi, M.; Dyrskjot, L.; Loriot, Y.; Gupta, S.; Colecchia, M.; Spiess, P. E.; Ross, J. S.; Necchi, A. | |
| The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC) | 1-gen-2024 | Tateo, V.; Gibb, E.; Mercinelli, C.; Raggi, D.; Cigliola, A.; Patane, D. A.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Avesani, G.; Briganti, A.; Montorsi, F.; Santini, D.; Necchi, A. | |
| Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials | 1-gen-2024 | Cigliola, A.; Basile, G.; Mercinelli, C.; Raggi, D.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Colombo, R.; Avesani, G.; Re, C.; Briganti, A.; Montorsi, F.; Necchi, A. | |
| Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer | 1-gen-2024 | Necchi, A.; Basile, G.; Gibb, E. A.; Raggi, D.; Calareso, G.; De Padua, T. C.; Patane, D.; Crupi, E.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Giannatempo, P.; Moschini, M.; Briganti, A.; Montorsi, F.; Messina, A.; Ross, J. S.; Pavlick, D.; De Cobelli, F.; Brembilla, G. |